NASDAQ:ABEO Abeona Therapeutics (ABEO) Stock Price, News & Analysis $5.68 +0.01 (+0.09%) As of 11:08 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Abeona Therapeutics Stock (NASDAQ:ABEO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Abeona Therapeutics alerts:Sign Up Key Stats Today's Range$5.60▼$5.7850-Day Range$4.76▼$6.0152-Week Range$4.00▼$7.54Volume149,729 shsAverage Volume1.15 million shsMarket Capitalization$323.42 millionP/E Ratio5.84Dividend YieldN/APrice Target$19.00Consensus RatingHold Company Overview Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need. The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa. These candidates have advanced through early‐stage trials, offering initial proof of concept in delivering corrective genetic material to affected tissues. Abeona is also exploring innovative oncology cell therapy approaches that apply its gene delivery expertise to tumor targeting. Abeona supports its pipeline with cGMP manufacturing facilities in Cleveland and Cambridge, complemented by a research presence in the Texas Medical Center to scale vector production and process development. The company has forged strategic collaborations to streamline clinical supply and broaden patient access, reflecting its commitment to advancing transformative medicines globally. Under the guidance of its executive leadership, Abeona continues to engage with regulatory authorities and expand clinical trial initiatives across North America and Europe.AI Generated. May Contain Errors. Read More Abeona Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreABEO MarketRank™: Abeona Therapeutics scored higher than 53% of companies evaluated by MarketBeat, and ranked 499th out of 855 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingAbeona Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAbeona Therapeutics has a consensus price target of $19.00, representing about 233.0% upside from its current price of $5.71.Amount of Analyst CoverageAbeona Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Abeona Therapeutics' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Abeona Therapeutics are expected to grow in the coming year, from ($0.79) to ($0.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Abeona Therapeutics is 5.88, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.96.Price to Earnings Ratio vs. SectorThe P/E ratio of Abeona Therapeutics is 5.88, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.98.Price to Book Value per Share RatioAbeona Therapeutics has a P/B Ratio of 1.94. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Abeona Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted27.18% of the float of Abeona Therapeutics has been sold short.Short Interest Ratio / Days to CoverAbeona Therapeutics has a short interest ratio ("days to cover") of 16.41, which indicates bearish sentiment.Change versus previous monthShort interest in Abeona Therapeutics has recently decreased by 0.51%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAbeona Therapeutics does not currently pay a dividend.Dividend GrowthAbeona Therapeutics does not have a long track record of dividend growth. News and Social Media1.5 / 5News Sentiment-0.63 News SentimentAbeona Therapeutics has a news sentiment score of -0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Abeona Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 8 people have searched for ABEO on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat Follows2 people have added Abeona Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Abeona Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $994,940.00 in company stock.Percentage Held by Insiders7.10% of the stock of Abeona Therapeutics is held by insiders.Percentage Held by Institutions80.56% of the stock of Abeona Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Abeona Therapeutics' insider trading history. Receive ABEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abeona Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABEO Stock News HeadlinesChristine Berni Silverstein Sells 18,160 Shares of Abeona Therapeutics (NASDAQ:ABEO) StockJune 16 at 4:38 AM | insidertrades.comAbeona Therapeutics announces resignation of board memberJune 12, 2026 | tipranks.comRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the largest mineral reserve in the country - enough gold for a new Fort Knox, enough copper to rebuild the U.S. electric grid 25 times over. The Trump administration has previously staked positions in MP Materials, Lithium America, Trilogy Metals, and USA Rare Earth - each time shares moved higher. A landmark policy decision expected before June 30 could reprice this stock from $2 to $20 or more within a year.June 16 at 1:00 AM | Paradigm Press (Ad)Abeona Therapeutics Updates Investor Presentation Under Regulation FDJune 10, 2026 | tipranks.comMadhav Vasanthavada Sells 4,170 Shares of Abeona Therapeutics (NASDAQ:ABEO) StockJune 10, 2026 | insidertrades.comAbeona Advances ABO-701 T-Cell Therapy Toward INDJune 4, 2026 | tipranks.comMark Alvino Sells 6,500 Shares of Abeona Therapeutics (NASDAQ:ABEO) StockMay 23, 2026 | insidertrades.comInsider Selling: Abeona Therapeutics (NASDAQ:ABEO) Director Sells 26,143 Shares of StockMay 16, 2026 | insidertrades.comSee More Headlines ABEO Stock Analysis - Frequently Asked Questions How have ABEO shares performed this year? Abeona Therapeutics' stock was trading at $5.27 on January 1st, 2026. Since then, ABEO stock has increased by 8.3% and is now trading at $5.7050. How were Abeona Therapeutics' earnings last quarter? Abeona Therapeutics Inc. (NASDAQ:ABEO) posted its quarterly earnings data on Wednesday, May, 13th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.33) by $0.03. The biopharmaceutical company earned $8.72 million during the quarter, compared to the consensus estimate of $4.57 million. Read the conference call transcript. When did Abeona Therapeutics' stock split? Shares of Abeona Therapeutics reverse split before market open on Tuesday, July 5th 2022.The 1-25 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. Who are Abeona Therapeutics' major shareholders? Abeona Therapeutics' top institutional investors include AIGH Capital Management LLC (5.45%), Simplify Asset Management Inc. (0.89%), Bank of America Corp DE (0.69%) and Sei Investments Co. (0.30%). Insiders that own company stock include Vishwas Seshadri, Joseph Walter Vazzano, Brendan M O'malley, Madhav Vasanthavada, Leila Alland, Faith L Charles, Christine Berni Silverstein, Michael Amoroso, Mark Alvino and Eric Crombez. View institutional ownership trends. How do I buy shares of Abeona Therapeutics? Shares of ABEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Abeona Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Abeona Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), GE Aerospace (GE). Company Calendar Last Earnings5/13/2026Today6/16/2026Next Earnings (Estimated)8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (7m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 ABEO's financial health is in the Red zone, according to TradeSmith. ABEO has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ABEO Previous SymbolOTCMKTS:ACCP CIK318306 Webwww.abeonatherapeutics.com Phone214-665-9495Fax214-905-5101Employees90Year Founded2013Price Target and Rating Average Price Target for Abeona Therapeutics$19.00 High Price Target$20.00 Low Price Target$17.00 Potential Upside/Downside+233.0%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)$0.97 Trailing P/E Ratio5.88 Forward P/E RatioN/A P/E GrowthN/ANet Income$71.18 million Net MarginsN/A Pretax Margin455.56% Return on Equity-53.98% Return on Assets-38.52% Debt Debt-to-Equity Ratio0.03 Current Ratio5.89 Quick Ratio5.70 Sales & Book Value Annual Sales$5.82 million Price / Sales55.86 Cash FlowN/A Price / Cash FlowN/A Book Value$2.94 per share Price / Book1.94Miscellaneous Outstanding Shares56,990,000Free Float52,948,000Market Cap$325.13 million OptionableOptionable Beta1.35 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:ABEO) was last updated on 6/16/2026 by MarketBeat.com Staff. From Our PartnersDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | Sponsored"You'll own nothing and be happy" (it's not a theory anymore)Since 1913, the evidence is clear… Once they force everyone onto CBDCs, there will be no escape. Every tran...Decentralized Masters | SponsoredThis Could Be the Biggest Monetary Shift in 50 YearsTucked inside U.S. Code Title 31, Section 5117 is a provision allowing the Treasury to reprice America's gold ...Americas Gold Company | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredNuclear Is Back. The Next Market May Be Uranium.Nuclear is moving back to the center of America's power strategy. AI data centers need reliable electricity, a...i2i Marketing Group, LLC | SponsoredHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abeona Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Abeona Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
